Inflammatory Marker Predicts ALS Disability and Survival, Supporting Development of Neuraltus Therapy NP001

Measuring blood levels of the inflammatory marker C-reactive protein (CRP) in patients with amyotrophic lateral sclerosis (ALS) can help physicians track the disease, according to an Italian study of 394 people with ALS. Neuraltus Pharmaceuticals of San Bruno, Calif., believes this study further supports the idea that ALS may respond to inflammation-modulating…

Brains of ALS Patients ‘Wired’ Differently and That’s Evident in Disability, Study Says

Patients with amyotrophic lateral sclerosis (ALS) have a different functional brain network than healthy individuals, and that difference appears to be strongly associated with disability, according to new research. This finding supports previous research suggesting that monitoring a patient’s brain for changes in its neuronal network can aid in evaluating ALS disability and likely disease progression. The study,…